POST Online Media Lite Edition



 

Takeda gets clearance for Shire deal from U.S. FTC

Staff Writer |
Takeda Pharmaceutical has been given permission by the U.S. consumer protection agency for its takeover of UK drug-maker Shire.

Article continues below




Takeda said on Tuesday morning that its has received unconditional clearance from the Federal Trade Commission for the proposed acquisition.

The deal remains subject to a number of conditions, including receipt of other regulatory clearances and approval by the shareholders of both companies.

"The FTC's unconditional clearance of the acquisition is another significant milestone in the transaction process," Takeda said.


What to read next

Shire sells cancer drugs to Servier for $2.4 billion
Shire mulling new offer from Takeda
Shire board 'would be willing' to recommend £46 billion Takeda deal